Discover
GOSS
Gossamer Bio, Inc.
10.73
1 x 10.69
1 x 12.30
bid
ask
-
1.21
10.13%
1 @ 07:44 PM
11.36 +0.63 (5.91%)
| Ytd | -95.67% | |
| 1y | -95.65% |
10.68
day range
12.49
10.38
52 week range
303.20
| Open | 12.00 | Prev Close | 11.94 | Low | 10.68 | High | 12.49 | Mkt Cap | 65.63M |
| Vol | 530.22K | Avg Vol | 349.56K | EPS | -52.80 | P/E | N/A | Forward P/E | -0.69 |
| Beta | 2.00 | Short Ratio | 3.80 | Inst. Own | 77.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 13.18 | 200-d Avg | 78.80 | 1yr Est | 132.48 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -3.69 | N/A | N/A | N/A |
| 2026-08-13 | 2026-06 | -9.87 | -0.2 | 9.67 | 97.97% |
| 2026-05-18 | 2026-03 | -13.6 | -0.2 | 13.4 | 98.53% |
| 2026-03-18 | 2025-12 | -16 | -0.21 | 15.79 | 98.69% |
| 2025-11-06 | 2025-09 | -15.2 | -16.8 | -1.6 | -10.53% |
| 2025-08-11 | 2025-06 | -14.4 | -0.17 | 14.23 | 98.82% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-14 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-07-28 | Leerink Partners | Upgrade | Market Perform | Outperform |
| 2026-07-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-19 | Barclays | Upgrade | Underweight | Underweight |
Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-01 | ARANDA RICHARD | Officer | 465.65K | Stock Award(Grant) |
| 2026-01-01 | CHRISTIAN WAAGE | Officer | 882.18K | Stock Award(Grant) |
| 2026-01-01 | GIRAUDO BRYAN M. | Chief Operating Officer | 869.75K | Stock Award(Grant) |
| 2026-01-01 | HASNAIN FAHEEM | Chief Executive Officer | 6.25M | Stock Award(Grant) |
| 2025-08-18 | MILLIGAN SANDRA | Director | 58.05K | Purchase |
| 2026-01-01 | PETERSON CARYN | Officer | 259.33K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Shaw D.E. & Co., Inc. | 40.96M | 439.49M | 8.38% |
| 2026-06-29 | 683 Capital Management LLC | 39.20M | 420.60M | 8.02% |
| 2026-06-29 | DeepCurrents Investment Group, LLC | 37.67M | 404.15M | 7.70% |
| 2026-06-29 | Context Capital Management, LLC | 28.95M | 310.60M | 5.92% |
| 2026-06-29 | Worth Venture Partners, Llc | 25.02M | 268.44M | 5.12% |
| 2026-06-29 | AQR Capital Management, LLC | 15.63M | 167.71M | 3.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 6.91M | 74.15M | 1.41% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.24M | 24.07M | 0.46% |
| 2026-06-29 | iShares Trust-iShares Biotechnology ETF | 1.50M | 16.11M | 0.31% |
| 2026-05-30 | SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 986.83K | 10.59M | 0.20% |
| 2026-05-30 | VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 977.03K | 10.48M | 0.20% |
| 2026-05-30 | VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 541.95K | 5.82M | 0.11% |